Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer

Exclusion Criteria

• •Cohort 1
• •1. Prior invasive breast cancer diagnosis.
• •2. Other invasive malignancy within 5 years before or after breast cancer diagnosis
• •3. Non-luminal breast cancer (defined as estrogen-receptor \< 10%).
• •4. Patients who were unable to complete at least 80% of 5-year initial treatment with tamoxifen.
• •5. Uncertain menopausal status (unable to evaluate menopausal status according to aforementioned definitions).
• •6. Recurrent or metastatic breast cancer within or after 5-year initial treatment with tamoxifen (DCIS-only is allowed at any time before or after breast cancer diagnosis).
• •8\) Unable to give informed consent in Swedish. Cohort 2
• •1. Prior invasive breast cancer diagnosis.
• •2. Other invasive malignancy within 5 years before or after breast cancer diagnosis; non-Luminal breast cancer (defined as estrogen-receptor \< 10%).
• •3. Patients who were unable to complete at least 80% of 5-year initial treatment with AI.
• •4. Recurrent or metastatic breast cancer within or after 5-year initial treatment with AI (DCIS-only is allowed at any time before or after breast cancer diagnosis).
• •6\) No contraindication for tamoxifen therapy. 7) Unable to give informed consent in Swedish.